Cargando…
Haploidentical bone marrow transplant with posttransplant cyclophosphamide for sickle cell disease: An update
Hematopoietic cell transplant (HCT) can cure both children and adults with sickle cell disease. Outcomes have historically been poor for the vast majority of patients who lack a matched sibling donor. However, the development of haploidentical HCT (haplo-HCT) with high doses of posttransplant cyclop...
Autores principales: | Patel, Dilan A., Akinsete, Adeseye M., de la Fuente, Josu, Kassim, Adetola A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
King Faisal Specialist Hospital & Research Centre. Published by Elsevier Ltd.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7118612/ https://www.ncbi.nlm.nih.gov/pubmed/32202252 http://dx.doi.org/10.1016/j.hemonc.2020.01.002 |
Ejemplares similares
-
New‐onset posttransplant diabetes mellitus after haploidentical hematopoietic cell transplantation with posttransplant cyclophosphamide
por: Mangan, Brendan L., et al.
Publicado: (2020) -
Total marrow and lymphoid irradiation as conditioning in haploidentical transplant with posttransplant cyclophosphamide
por: Al Malki, Monzr M., et al.
Publicado: (2022) -
Progressive substitution of posttransplant cyclophosphamide with bendamustine: A phase I study in haploidentical bone marrow transplantation
por: Katsanis, Emmanuel, et al.
Publicado: (2020) -
Haploidentical Hematopoietic Cell Transplantation Using Posttransplant Cyclophosphamide for Sézary Syndrome
por: Kanda-Kato, Madoka, et al.
Publicado: (2020) -
The impact of Host vs. Graft mismatches on rejection of haploidentical bone marrow transplants in thalassemia patients using posttransplant cyclophosphamide
por: Marwah, Priya, et al.
Publicado: (2019)